GT201500233A - BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS - Google Patents

BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS

Info

Publication number
GT201500233A
GT201500233A GT201500233A GT201500233A GT201500233A GT 201500233 A GT201500233 A GT 201500233A GT 201500233 A GT201500233 A GT 201500233A GT 201500233 A GT201500233 A GT 201500233A GT 201500233 A GT201500233 A GT 201500233A
Authority
GT
Guatemala
Prior art keywords
estrogen
receivers
compositions
selective
benzotiophen
Prior art date
Application number
GT201500233A
Other languages
Spanish (es)
Inventor
Burks Heather Elizabeth
Michael A Dechantsreiter
He Guo
Nunez Jill
Peukert Stefan
Springer Clayton
Sun Yingchuan
Thomsen Noel Marie-France
Tria George Scott
Yu Bing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201500233A publication Critical patent/GT201500233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS Y COMPOSICIONES QUE SON POTENTES ANTAGONISTAS DE LA SEÑALIZACIÓN DE LOS RECEPTORES DE ESTRÓGENO Y DEGRADANTES SELECTIVOS DE LOS RECEPTORES DE ESTRÓGENO (SERDS). LA INVENCIÓN PROPORCIONA ADEMÁS UN PROCESO PARA LA PREPARACIÓN DE LOS COMPUESTOS DE LA INVENCIÓN, PREPARACIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, Y LOS MÉTODOS PARA UTILIZAR TALES COMPUESTOS Y COMPOSICIONES EN EL MANEJO DE ENFERMEDADES O TRASTORNOS ASOCIADOS CON UNA ACTIVIDAD ABERRANTE DE LOS RECEPTORES DE ESTRÓGENOSTHE PRESENT INVENTION REFERS TO COMPOUNDS AND COMPOSITIONS THAT ARE POWERFUL ANTAGONISTS OF THE SIGNALING OF THE ESTROGEN RECEIVERS AND SELECTIVE DEGRADERS OF THE ESTROGEN RECEIVERS (SERDS). THE INVENTION ALSO PROVIDES A PROCESS FOR THE PREPARATION OF THE COMPOUNDS OF THE INVENTION, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THESE COMPOUNDS, AND THE METHODS FOR USING SUCH COMPOUNDS AND COMPOSITIONS IN THE MANAGEMENT OF DISEASES OR DISORDERS ASSOCIATES

GT201500233A 2013-02-19 2015-08-19 BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS GT201500233A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766439P 2013-02-19 2013-02-19

Publications (1)

Publication Number Publication Date
GT201500233A true GT201500233A (en) 2016-01-21

Family

ID=50239942

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500233A GT201500233A (en) 2013-02-19 2015-08-19 BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS

Country Status (46)

Country Link
US (5) US8877801B2 (en)
EP (2) EP3360870A1 (en)
JP (1) JP6364028B2 (en)
KR (1) KR102279999B1 (en)
CN (1) CN105008343B (en)
AP (1) AP2015008618A0 (en)
AR (1) AR094704A1 (en)
AU (1) AU2014219283C1 (en)
BR (1) BR112015018882B1 (en)
CA (1) CA2899030C (en)
CL (1) CL2015002098A1 (en)
CR (1) CR20150424A (en)
CU (1) CU24337B1 (en)
CY (1) CY1120155T1 (en)
DK (1) DK2958907T3 (en)
DO (1) DOP2015000202A (en)
EA (1) EA028032B1 (en)
ES (1) ES2671516T3 (en)
GE (1) GEP201706638B (en)
GT (1) GT201500233A (en)
HK (2) HK1211941A1 (en)
HR (1) HRP20180816T1 (en)
HU (1) HUE039052T2 (en)
IL (1) IL240131B (en)
JO (1) JO3494B1 (en)
LT (1) LT2958907T (en)
MA (1) MA38325B1 (en)
ME (1) ME03061B (en)
MX (1) MX359471B (en)
MY (1) MY174888A (en)
NI (1) NI201500106A (en)
NO (1) NO3077717T3 (en)
NZ (1) NZ710385A (en)
PE (1) PE20151428A1 (en)
PH (1) PH12015501832A1 (en)
PL (1) PL2958907T3 (en)
PT (1) PT2958907T (en)
RS (1) RS57106B1 (en)
SG (1) SG11201505697VA (en)
SI (1) SI2958907T1 (en)
TN (1) TN2015000323A1 (en)
TR (1) TR201806882T4 (en)
TW (1) TWI612040B (en)
UY (1) UY35334A (en)
WO (1) WO2014130310A1 (en)
ZA (1) ZA201505305B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2958907T3 (en) 2013-02-19 2018-06-06 Novartis Ag Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders
KR20170118687A (en) 2015-02-19 2017-10-25 제이엔씨 주식회사 Liquid crystalline compound having benzothiophene, liquid crystal composition and liquid crystal display element
TWI708770B (en) 2015-06-08 2020-11-01 日商捷恩智股份有限公司 Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device
US20170166551A1 (en) * 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2017172957A1 (en) 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (en) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド Combination therapy for cancer treatment
TW201835064A (en) * 2017-02-10 2018-10-01 美商G1治療公司 Benzothiophene estrogen receptor modulators
US11179365B2 (en) 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
WO2019106604A1 (en) 2017-12-01 2019-06-06 Novartis Ag Pharmaceutical combination comprising lsz102 and alpelisib
KR20200113229A (en) * 2018-01-22 2020-10-06 래디어스 파마슈티컬스, 인코포레이티드 Estrogen receptor-modulating compounds
WO2019157020A1 (en) * 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
AU2019321677A1 (en) * 2018-08-16 2021-03-11 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators to treat medical disorders
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EA202192019A1 (en) 2019-02-15 2021-11-02 Новартис Аг DERIVATIVES OF 3- (1-OXO-5- (PIPERIDIN-4-YL) ISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND ROUTES OF THEIR APPLICATION
CN113329792A (en) 2019-02-15 2021-08-31 诺华股份有限公司 Substituted 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
EP3972651A2 (en) 2019-05-20 2022-03-30 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20220044528A (en) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 Estrogen receptor modulators to treat mutants
BR112022011902A2 (en) 2019-12-20 2022-09-06 Novartis Ag COMBINATION THERAPIES
CN111057065B (en) * 2019-12-24 2021-04-23 沈阳药科大学 Preparation method and application of thienopyrimidine compound
CN111646972B (en) * 2020-06-12 2021-06-29 上海皓元医药股份有限公司 Preparation method of selective estrogen receptor degradation agent and intermediate thereof
MX2022015852A (en) 2020-06-23 2023-01-24 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6- dione derivatives.
EP4175638A1 (en) * 2020-07-06 2023-05-10 Tactogen Inc. Advantageous benzothiophene compositions for mental disorders or enhancement
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021385349A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
IL303059A (en) 2020-11-24 2023-07-01 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
WO2022140744A1 (en) 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CN116265458A (en) * 2021-12-17 2023-06-20 中国科学院上海药物研究所 Benzothiophene derivative, preparation method and application thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN115710248A (en) * 2022-11-18 2023-02-24 南京中医药大学 Novel selective estrogen receptor down-regulator compounds, methods of preparation and uses

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (en) 1964-04-29 1967-10-15 Nestle Sa Process for the preparation of high molecular weight inclusion compounds
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
JPS6041077B2 (en) 1976-09-06 1985-09-13 喜徳 喜谷 Cis platinum(2) complex of 1,2-diaminocyclohexane isomer
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
ZA822247B (en) * 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
SI0729956T1 (en) * 1995-02-28 2002-04-30 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
PT842169E (en) * 1995-06-26 2001-04-30 Lilly Co Eli BENZOYOPHENE COMPOUNDS
US5731342A (en) 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
CA2331120A1 (en) 1998-05-12 1999-11-18 Iwan Gunawan Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2004500389A (en) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of PPAR mediators in therapy
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7425565B2 (en) 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
EA008379B1 (en) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Phosphorus-containing compounds & uses thereof
DE60321141D1 (en) 2002-03-05 2008-07-03 Axys Pharm Inc Cathepsin-cystein-protease-hemmer
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
JP4656939B2 (en) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー Selective estrogen receptor modulators containing phenylsulfonyl groups
DE602004016331D1 (en) 2003-06-10 2008-10-16 Lilly Co Eli PENTAFLUOROALKYLSULFIN-NAPHTHALINE AND ASSOCIATED ESTROGEN RECEPTOR MODULATORS
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
ATE448215T1 (en) * 2004-01-22 2009-11-15 Lilly Co Eli SELECTIVE ESTROGEN RECEPTOR MODULATORS
WO2005073205A1 (en) 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US20080227814A1 (en) 2004-01-29 2008-09-18 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2125774A1 (en) 2007-03-16 2009-12-02 Eli Lilly & Company Process and intermediates for preparing arzoxifene
US20090069380A1 (en) 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched aroxifene
PE20140100A1 (en) 2007-09-12 2014-02-12 Genentech Inc COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITING COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS
CN101909631B (en) 2007-10-25 2012-09-12 健泰科生物技术公司 Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102477033A (en) * 2010-11-23 2012-05-30 苏州波锐生物医药科技有限公司 Benzothiophene compound and application thereof in preventive and/or treatment medicine for breast cancer and osteoporosis
WO2012084711A1 (en) 2010-12-24 2012-06-28 Msd Oss B.V. N-substituted azetidine derivatives
DK2958907T3 (en) 2013-02-19 2018-06-06 Novartis Ag Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders

Also Published As

Publication number Publication date
US9931317B2 (en) 2018-04-03
AU2014219283A1 (en) 2015-08-13
US9561211B2 (en) 2017-02-07
IL240131B (en) 2018-11-29
PH12015501832B1 (en) 2015-11-09
PH12015501832A1 (en) 2015-11-09
JP2016509022A (en) 2016-03-24
CL2015002098A1 (en) 2015-11-13
EP2958907B1 (en) 2018-02-28
DK2958907T3 (en) 2018-06-06
CU24337B1 (en) 2018-04-03
WO2014130310A1 (en) 2014-08-28
BR112015018882B1 (en) 2021-09-14
BR112015018882A2 (en) 2017-07-18
RS57106B1 (en) 2018-06-29
AU2014219283B2 (en) 2015-10-29
SG11201505697VA (en) 2015-09-29
CN105008343A (en) 2015-10-28
US20170112805A1 (en) 2017-04-27
HK1211941A1 (en) 2016-06-03
PT2958907T (en) 2018-03-23
AR094704A1 (en) 2015-08-19
US8877801B2 (en) 2014-11-04
NO3077717T3 (en) 2018-07-21
UY35334A (en) 2014-09-30
IL240131A0 (en) 2015-09-24
CN105008343B (en) 2017-12-08
HRP20180816T1 (en) 2018-06-29
JO3494B1 (en) 2020-07-05
ZA201505305B (en) 2016-09-28
LT2958907T (en) 2018-04-25
MX2015010752A (en) 2015-11-30
EA201591537A1 (en) 2015-12-30
CA2899030A1 (en) 2014-08-28
JP6364028B2 (en) 2018-07-25
AP2015008618A0 (en) 2015-07-31
HUE039052T2 (en) 2018-12-28
US20140235660A1 (en) 2014-08-21
US10058534B2 (en) 2018-08-28
CR20150424A (en) 2015-10-19
TWI612040B (en) 2018-01-21
MA38325A2 (en) 2016-12-30
ES2671516T3 (en) 2018-06-06
GEP201706638B (en) 2017-03-10
CY1120155T1 (en) 2018-12-12
CU20150090A7 (en) 2016-04-25
MX359471B (en) 2018-09-28
NZ710385A (en) 2016-10-28
EA028032B1 (en) 2017-09-29
MY174888A (en) 2020-05-20
US20180169063A1 (en) 2018-06-21
TR201806882T4 (en) 2018-06-21
NI201500106A (en) 2015-10-20
KR102279999B1 (en) 2021-07-22
US20150361065A1 (en) 2015-12-17
US20160184265A1 (en) 2016-06-30
KR20150119385A (en) 2015-10-23
SI2958907T1 (en) 2018-05-31
ME03061B (en) 2019-01-20
PE20151428A1 (en) 2015-09-24
US9321746B2 (en) 2016-04-26
AU2014219283C1 (en) 2016-10-27
EP2958907A1 (en) 2015-12-30
MA38325A3 (en) 2018-05-31
DOP2015000202A (en) 2015-11-30
TW201443034A (en) 2014-11-16
PL2958907T3 (en) 2018-07-31
TN2015000323A1 (en) 2017-01-03
CA2899030C (en) 2021-03-09
HK1251227A1 (en) 2019-01-25
EP3360870A1 (en) 2018-08-15
MA38325B1 (en) 2019-03-29

Similar Documents

Publication Publication Date Title
GT201500233A (en) BENZOTIOPHEN DERIVATIVES AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE ESTROGEN RECEIVERS
CO2018006714A2 (en) 3-azabicyclo [3.1.0] substituted hexanes as ketohexokinase inhibitors
GT201600147A (en) DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2
CR20150664A (en) MODULATORS OF ESTROGEN RECEIVERS AND THEIR USES
GT201400297A (en) NEW TIENOPIRIMIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY36950A (en) USEFUL COMPOUNDS AS INHIBITORS OF PROTEIN-PROTEIN INTERACTION PD-1 / PD-L1 AND CD80 / PD-L1 AND COMPOSITIONS CONTAINING THEM
UY36076A (en) USEFUL COMPOUNDS AS INHIBITORS OF THE PROTEINAPROTEIN INTERACTION PD-1 / PD-L1 AND CD80 / PD-L1, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CY1123953T1 (en) DELAYED RELEASE COMPOSITIONS OF LINACLOTIDE
CR20160033A (en) AUTOTAXIN INHIBITORS UNDERSTANDING A HETEROAROMATIC-BENCIL-AMIDA CYCLING NUCLEUS
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MX2015011132A (en) Polycyclic estrogen receptor modulators and uses thereof.
CL2014001853A1 (en) Compounds derived from substituted pyrrole; preparation procedure; pharmaceutical composition that contains them; pharmaceutical combination; use to treat diseases such as cancers and immune system diseases.
CL2016000063A1 (en) New indolizine derivatives, their preparation procedure and the pharmaceutical compositions containing them.
CO2019012767A2 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compound
UY35906A (en) NEWS DERIVED FROM BENCIMIDAZOL AS LIGANDOS OF EP4
ECSP16074478A (en) NOVEL COMPOUNDS
UY34356A (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CL2017001073A1 (en) 2,4 diamino-quinolia substituted as new anticancer agents
UY35653A (en) NEW DERIVATIVES OF INDOL AND PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PE20150371A1 (en) INDOLCARBONITRILES AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR
CL2015002712A1 (en) Laquinimod sodium crystals and process for preparing them
CR20160042A (en) V1a ANTAGONISTS TO TREAT SLEEP DISORDERS BY PHASE CHANGE
UY34761A (en) PARASITICIDE COMPOSITIONS THAT INCLUDE DERIVATIVES OF BENZIMIDAZOL, METHODS AND USES OF THE SAME.
CO2018004665A2 (en) Oxadiazoespiric compounds